American Joint Committee on Cancer eighth edition human papilloma virus positive oropharyngeal cancer staging system: Discordance between clinical and pathological staging systems

Head & Neck ◽  
2019 ◽  
Author(s):  
Scott R. Hall ◽  
Gregory S. Neel ◽  
Brent A. Chang ◽  
Brittany E. Howard ◽  
Thomas H. Nagel ◽  
...  
Keyword(s):  
Human Papilloma Virus ◽  
Oropharyngeal Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Papilloma Virus ◽  
Pathological Staging ◽  
American Joint Committee ◽  
Staging Systems ◽  
Eighth Edition

Application of the Eighth Edition American Joint Committee on Cancer Staging System for HPV-Related Oropharyngeal Cancer Treated With Transoral Robotic Surgery

2017 ◽  
Vol 128 (5) ◽  
pp. 1133-1139 ◽  
Author(s):  
Arvind K. Badhey ◽  
Ashley Olson ◽  
Sameep Kadakia ◽  
Jack Russo ◽  
Peter Ting ◽  
...  
Keyword(s):  
Robotic Surgery ◽  
Oropharyngeal Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Transoral Robotic Surgery ◽  
American Joint Committee ◽  
Eighth Edition

Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer

Head & Neck ◽  
2017 ◽  
Vol 40 (3) ◽  
pp. 457-466 ◽  
Author(s):  
John D. Cramer ◽  
Kate E. Hicks ◽  
Alfred W. Rademaker ◽  
Urjeet A. Patel ◽  
Sandeep Samant
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
American Joint Committee ◽  
Eighth Edition

scholarly journals Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system

2019 ◽  
Vol 80 (1) ◽  
pp. 272-274 ◽  
Author(s):  
Lena A. von Schuckmann ◽  
Maria Celia B. Hughes ◽  
Rebecca Lee ◽  
Paul Lorigan ◽  
Kiarash Khosrotehrani ◽  
...  
Keyword(s):  
Staging System ◽  
Cancer Staging ◽  
American Joint Committee ◽  
Eighth Edition

scholarly journals Prognostic Validity of the American Joint Committee on Cancer Eighth Edition Staging System for Well-Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Multinational Multicenter Study

2020 ◽  
Author(s):  
Hebin Wang ◽  
Ding Ding ◽  
Tingting Qin ◽  
Jun Liu ◽  
Hang Zhang ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Staging System ◽  
Tnm Staging ◽  
Stage I ◽  
Pancreatic Neuroendocrine Tumors ◽  
American Joint Committee ◽  
Staging Systems ◽  
Significant Difference ◽  
Well Differentiated ◽  
Eighth Edition

Abstract Background:There is no widely-accepted staging system for pancreatic neuroendocrine tumors (pNETs). The aim of this study was to validate the American Joint Committee on Cancer (AJCC) 8th edition staging system for well-differentiated (G1/G2) pNETs.Methods:A multicenter dataset (n=1086) was used to evaluate the application of the AJCC 7th and 8th, the European Neuroendocrine Tumor Society (ENETS), and the modified ENETS (mENETS) staging systems for well-differentiated pNETs.Results:The proportion of patients with stage III tumors was extremely low (1.1%) according to the AJCC 7th staging system. For the ENETS staging system, patients with stage IIIA disease had worse estimated mean survival than patients with stage IIIB disease (78.9 vs. 107.3 months). When comparing with patients in stage I, the AJCC 7th, ENETS, and mENETS staging systems showed good performance in discriminating between stages; however, there was no significant difference in some stages when the reference was defined as the earlier stage. When the reference was defined as stage I or the earlier stage, there was a significant inter-stage difference in the AJCC 8th staging system.Conclusions:The AJCC 8th staging system is more suitable for pNETs than other TNM staging systems and may be adopted in clinical practice.

Incorporating Biology Into Breast Cancer Staging: American Joint Committee on Cancer, Eighth Edition, Revisions and Beyond

2018 ◽  
pp. 38-46 ◽  
Author(s):  
Elizabeth A. Mittendorf ◽  
John M. S. Bartlett ◽  
Daphne L. Lichtensztajn ◽  
Sarat Chandarlapaty
Keyword(s):  
Breast Cancer ◽  
Tumor Biology ◽  
Staging System ◽  
Cancer Staging ◽  
Her2 Status ◽  
Breast Cancer Staging ◽  
Pathologic Evaluation ◽  
Staging Systems ◽  
Eighth Edition ◽  
The Impact

Higher-quality imaging, refined surgical procedures, enhanced pathologic evaluation, and improved understanding of the impact of tumor biology on treatment and prognosis have necessitated revisions of the AJCC breast cancer staging system. The eighth edition includes clinical and pathologic prognostic stages that incorporate biologic variables—grade, estrogen and progesterone receptor status, HER2 status, and multigene panels—with the anatomic extent of disease defined by tumor, node, and metastasis categories. The prognostic staging systems facilitate more refined stratification with respect to survival than anatomic stage alone. Because the prognostic staging systems are dependent on biologic factors, accuracy is dependent on rigorous pathologic evaluation of tumors and on administration of treatment dictated by tumor biology. It is anticipated that technological advances will facilitate even more refined determination of underlying biology within tumors and in the peripheral blood, which increasingly is being evaluated as a compartment that reflects the primary tumor and sites of distant metastases. Diseases should be staged according to the eighth edition staging system to accurately reflect prognosis and to allow standardized data collection. Such standardization will facilitate assessment of the impact of advances in diagnosis and treatment of patients with breast cancer.

scholarly journals Clinical and prognostic impact of changes in the tnm system of the american joint committee for cancer, eighth edition, in patients with breast cancer

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Cynthia Mara Brito Lins Pereira ◽  
Yasmin de Farias Khayat ◽  
Mariana Rocha Bohone
Keyword(s):  
Breast Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Tnm Staging ◽  
Prognostic Impact ◽  
Tnm System ◽  
American Joint Committee ◽  
Therapeutic Decisions ◽  
Eighth Edition ◽  
The Impact

In Brazil, breast cancer is the first among the most prevalent malignancies in women, without considering non-melanoma skin cancer. However, in spite of the high number of deaths caused by breast cancer, there has been a great reduction in mortality rates and greater survival of patients with metastatic disease in the last decades. Such improvements are related to advances in treatment and greater knowledge about the biology of breast cancer. The American Joint Committee for Cancer (AJCC) cancer staging system is one of the important tools for doctors, and helps to predict disease progression and make therapeutic decisions. Therapeutic planning and prognosis of patients is possible through staging. Since the publication of the first edition of the Cancer Staging Manual, AJCC has insisted on seeing anatomical information. TNM staging (T: tumor; N: lymph nodes; M: metastasis). Limitations regarding this staging method were evidenced, as it is based only on anatomy and does not take biological factors into account. Through immunohistochemical study, breast cancer is subdivided into different molecular subtypes. When considering the modifications of the new edition of the TNM/AJCC system with respect to the prognostic and predictive factors of cancer, there may be a reclassification of patients, leading to a more reliable approach to their real disease condition. Objective: To analyze the impact generated by the update of the TNM/AJCC staging system (eighth edition), in the classification of patients with breast cancer seen at Hospital Ophir Loyola, a referral oncology hospital in the city of Belém, state of Pará, in 2018. Method: 176 medical records of patients undergoing treatment at Hospital Ophir Loyola, in 2018, were analyzed, which had information on the staging of the seventh edition and with immunohistochemical results. Result: 61.93% were between 40-60 years old, 46.2% were from the capital. Regarding the stage of diagnosis according to the 7th edition, 23 patients (13%) were in stage I, 66 cases (37.5%) in stage II, and the vast majority, totaling 77 cases (43.8%), in stage III. In addition, there were 03 cases (1.7%) in stage 0 (zero), and 07 cases (4%) in stage IV. There was a change in disease staging for 60.8% (107/176; 95%CI 53.4‒67.7) of the cases, 36.5% (39/107; 95%CI 28.0‒45.9) of these cases were upstaged, and in the others (63.5%, 68/107; 95%CI 54.1‒72.1), the change was to a lower prognostic category (down-staged). There was a significant increase in the proportion of cases staged in 2018 as IB and a significant reduction in cases staged by the most recent criterion such as IIB and IIIA (p<0.0001). Conclusion: the changes to new staging have shown to be more effective on the behavior of the tumor, helping in therapeutic decisions.

Sign in / Sign up

Export Citation Format

Share Document